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ABSTRACT
Lentiviral Vector Production at High Cell Density by Transient
Transfection of Suspended Culture HEK Cells
by
Jacob G. Accordino, Master of Science
Utah State University, 2022
Major Professor: Dr. D. Keith Roper
Department: Biological Engineering
Lentiviral vectors deliver functional genes to combat genetic diseases in seven
FDA-approved treatments, a host of clinical studies, and research in e.g., optogenetics.
Economic preparation of safe lentiviral vectors in quantities adequate to meet human
health needs remains an ongoing challenge. Production of plasmids used to generate and
package lentivirus via transient transfection of host cells is cost-prohibitive, transfection
efficiency is reduced at high cell densities, and variability in lentivirus yield is pervasive
in suspension production formats. This work investigates the transfection efficiencies and
lentiviral vector titers attainable by transient transfection of Human Embryonic Kidney
cells – cultured to high cell density in shake flasks – using commercially sourced cells,
growth medium, transfection reagent, supplement and enhancer, and packaging plasmids.
Human Embryonic Kidney cells were cultured to varying cell densities between
5.0 and 7.0 million cells per milliliter, then diluted to a density of 4.7 million cells per
milliliter with fresh culture medium to initiate the transfection process. Transfection was
accomplished using a proprietary cationic lipid-based transfection reagent, supplement,
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and enhancer. It was found that lentivirus produced per plasmid used can be increased
beyond previously reported values where vector production occurred at cell densities
above 4.0 million cells per milliliter. Transfection at 4.7 million cells per milliliter
supported increases in lentiviral productivity from 7.3 to 154 viral gene copies per cell
and specific plasmid productivity from approximately 7.3 million to 154 million viral
gene copies per microgram of plasmid, respectively, as viable cell density pretransfection increased from 5.1 million to 6.0 million cells per milliliter. Passaging of
cells at a frequency that maintains viability and mid-exponential growth prior to
transfection is important to achieve such increases.
The results of the present work provide a useful guide to intensify production of
lentiviral gene vectors via transient transfection at high cell densities.
(71 pages)
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PUBLIC ABSTRACT

Lentiviral Vector Production at High Cell Density by Transient
Transfection of Suspended Culture HEK Cells
Jacob G. Accordino

Viral vectors are gene carriers that efficiently deliver therapeutic gene constructs
to target cells. Viral vectors are frequently produced in suspension-growing cells of
mammalian origin, referred to as packaging cells. Lentiviral vectors have become widely
used as gene vectors since they were initially developed two and a half decades ago,
particularly in research settings. The advantages of lentiviral vectors for treating diseases
of genetic origin have driven research into their large-scale manufacture for clinical
settings. Currently, three main challenges exist that limit mass production of lentiviral
vectors. First, plasmid DNA used in the production process is very expensive. Second,
high vector titers have historically only been achievable at low packaging cell densities,
limiting the scalability of suspended-culture technologies. And third, vector production
frequently suffers from batch-to-batch variability in vector yield. In conjunction, these
challenges diminish the economic viability and practical implementation of industriallyscaled processes for lentiviral vector production.
Recent advances in commercial reagents can help mitigate these stated
challenges. There is currently a knowledge gap in the utility of cationic lipid-based
transfection reagents for producing lentivirus in suspended cultures at high cell density.
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In the present work, we investigate the production of lentiviral vectors by
transient transfection of high density Human Embryonic Kidney packaging cells with a
commercial cationic lipid transfection reagent. Several parameters in the production
process were monitored to identify sources of variability in vector titers. We found that as
packaging cells were cultured to increasing densities pre-transfection, there was a
corresponding increase in lentiviral vector yield. Further, we found that aside from preculture density, consistency in culture routine leading up to transfection had the most
significant influence on lentiviral vector yields.
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CHAPTER 1
INTRODUCTION

Background
Gene therapy is a branch of medical biotechnology that seeks to treat disease at
the level of the gene by introducing a functional gene (transgene) into a targeted cell. The
transgene acts in place of a defective gene which may be the cause of diseases like
muscular dystrophy or cystic fibrosis. Methods for delivering functional transgenes into a
cell are of two primary types: nonviral DNA vectors (i.e., introduction of DNA into cells
by synthetic means like a liposome), and viral vectors (i.e., incorporating the functional
gene into a non-replicating viral host).1 Viruses are useful gene therapy vehicles because
of their innate ability to infect cells and efficiently deliver genetic material to the cell
nucleus.
Viruses as gene transfer agents are generally more efficient in delivering a
functional transgene to a host cell than non-viral methods.2 Proteins on the outer surface
of the virus interact specifically with cell surface receptor. This triggers endocytosis of
the virus. Subsequent delivery of the transgene to the nucleus occurs for lentivirus as well
as other gene vectors. In the case of retroviruses, the viral genome is reverse transcribed
into complementary deoxyribonucleic acid (cDNA), which is then capable of being
integrated into the host cell genome for long-term functionality. For some retroviruses, a
state of cell division, which involves degradation of the nuclear envelope, is necessary for
integration.3
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Lentiviruses are a class of retrovirus that can transduce both replicating and nonreplicating cells, enabling greater gene transfer efficiency compared to other retrovirus
types. Lentiviral vectors (LVVs) as gene therapy vehicles allow for stable therapeutic
expression in transduced cells and provide potentially inheritable expression in daughter
cells.4 Additionally, LVVs have larger payloads, as large as 10 kb,5 compared to other
common viral vectors such as adenovirus, which are limited to 5 kb.6
State of the art LVVs are at a third generation of design, characterized by (1)
being self-inactivating vectors through deletion of promoter sequences in the 3’ long
terminal repeat (LTR) region, and (2) retaining only three of the nine genes present in
wildtype lentivirus.7 In transient LVV production systems, these three genes, gag, pol,
and rev, are typically separated onto two packaging plasmids, with a third plasmid
encoding genes to envelope the viral capsid (Figure 1).5 The transgene is incorporated
into a fourth plasmid, the backbone plasmid, between the LTR sequences.8
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Figure 1. Third-generation lentiviral vector genome. Packaging and envelope genes
from wildtype lentivirus are separated onto three plasmids with the gene of interest and
promoter sequences contained in a fourth plasmid. Adapted from Ghaleh, et al..9

LVVs can be generated in stable producer or stable packaging cell lines. Host
cells in these producer lines are often derived from Human Embryonic Kidney (HEK)
cells. In stable producer cells, all genes necessary for vector production are inserted into
the cells and either constitutively expressed or controlled by inducible systems.10 In
contrast, in stable packaging cells, only the gag-pol and rev genes are stably expressed,
and the transfer plasmid is transiently transfected to initiate vector production.11 While
stable producer and stable packaging systems are useful for continuous generation of
LVVs at high titers, they are prone to cytotoxicity from sustained expression of viral
packaging and envelope genes. Moreover, their development is a slow process, resulting
in lack of flexibility to changes in vector design.12,13
Transient transfection is an alternative to LVV production via stable producer or
stable packaging cells. In this approach, LVVs are produced via transient co-transfection
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of packaging and backbone plasmids into packaging cells. As with stable producer and
stable packaging methods, HEK cell derivatives are the most common packaging cells.
Advantages of transient transfection over stable cell methods include reduction of
cytotoxicity, and greater flexibility and speed in pseudotyping or otherwise editing of
vector constructs.14 Figure 2 illustrates the differences between packaging cell formats.

Figure 2. Comparison of lentiviral packaging cell types. Created with BioRender.com.

It is possible to produce LVV via transient transfection of packaging cells that are
either adherent to a culture plate or suspended in a culture flask with the former being the
most common method at developmental stages.15 Transient transfection of suspended
cells is more readily scalable to large stirred tank reactors to produce LVV at
manufacturing scale. Table 1 summarizes previous reports using shake flasks for
optimizing LVV production by transient transfection in batch or batch-replacement
modes. Refereed reports to date all recommended initiating transfection when packaging
cell densities were between 1 and 2 million cells per milliliter of medium. The most
common transfection reagent used was polyethylenimine (PEI), a cationic polymer.
Transfection with PEI is accomplished by mixing the negatively charged DNA vectors
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with the positively charged polymer to form a positively charged complex. The complex
is then added to the culture medium where the negatively charged cell membrane attracts
and engulfs the DNA-polymer complex.16 The procedure is less complicated than
transfection by calcium phosphate precipitation, another common transfection method,
which is highly sensitive to pH.8 Though inexpensive and simple to use, some reports
indicate transfection efficiency using PEI is lower than when DNA is complexed with a
cationic lipid-based transfection reagent. This is termed lipofection. In shake flask LVV
production, PEI-mediated transfection has achieved transfection efficiencies of up to 92%
and reached functional LVV titers between 106 and 108 transduction-capable LVVs per
milliliter (see Table 1). However, in adherent culture LVV production, lipofection can
achieve transfection efficiencies between 60% and nearly 100%.17,18 Little published data
exists on the transfection efficiency of suspended culture HEK cells by lipofection for
LVV production.
Currently, three main challenges exist to the large-scale manufacture of LVVs via
transient transfection: (1) large batch-to-batch variability; (2) a need for large mass of
plasmid to transfect the host cells; and (3) low cell densities used for transfection. Large
variations in LVV titer are common when scaling production from one volume and
format to another.11,19 This occurs even in cases where transfection experiments are
highly similar or identical.20 It has been speculated that poor reproducibility in vector
titers may come from the use of serum in culture medium,21,22 transfection by calcium
phosphate precipitation,16,23 or from differences in cell physiological state between
cultures.14,19,24
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Current protocols for transient transfection typically call for 1 – 2 ug of plasmid
per million cells (Table 1). For large plasmids (10,000+ bp), this means approximately
0.93 – 1.85 x 105 plasmid copies are required to transfect a single cell, though in reality
up to 106 copies may be required.25 Of those plasmids used in transfection, as few as 20 –
1,000 copies may successfully reach the cell nucleus following lipofection.26 Finally, it
has been observed that in transfection at densities higher than 1-2 million cells per
milliliter, a reduction in specific productivity occurs.19,27–29 Reduced specific LVV
productivity at cell densities greater than 1 to 2 million cells per milliliter limits
volumetric productivity of transient transfection. It presents a barrier to intensification of
LVV production during transient transfection. This reduces the inherent scalability
offered by suspended culture production formats.
The Thermo Fisher LV-MAX Lentiviral Production System could help address
challenges to large-scale manufacture of LVVs. The LV-MAX platform generates LVVs
through transient transfection of a suspension-adapted HEK293 packaging cell line with
plasmids encoding the necessary proteins to assemble a functional viral vector. Through
the use of chemically defined serum-free medium, transfection can be performed at
higher cell densities (>4.0 x 106 cells/mL) than those previously reported in benchtop
batch experiments (see Table 1). If transfection efficiency in LV-MAX media can be
maintained at increased cell density, this could increase the volumetric titer of LVVs. A
proprietary cationic lipid-based transfection reagent allows for high transfection
efficiency of HEK cells with minimal cytotoxicity. This may enable reducing the mass of
plasmid required for LVV production. The present study used the Thermo Fisher LVMAX Lentiviral Production System to examine its potential to (1) increase the cell
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density that can be efficiently transfected; (2) reduce the plasmid requirement; and (3)
maintain consistent batch-to-batch LVV yield.

Table 1. Specific productivities of lentiviral vectors (LVV) or virus-like particles
(VLP) produced in shake flasks by transient transfection of HEK cell derivatives.
Plasmid
Transfection
(ug) per
Method
106 Cells
PEI
1.0

Transfection
TU/ug
Cell Density TU/mL
TU/cell Ref.
plasmid
(cells/mL)
5.0 x 105
1.2 x 106 2.4 x 106
2.4
24
6
6
6
1.0 x 10
2.3 x 10
2.3 x 10
2.3
6
6
6
PEI
1.0
1.0 x 10
8.0 x 10
8.0 x 10
2.0
19
PEI
0.5
2.0 x 106
2.8 x 106 2.8 x 106
1.4
28a
6
6
5
PEI
1.5
1.0 x 10
1.0 x 10
6.7 x 10
1.0
20
1.0 x 106
6.0 x 105 4.0 x 105
0.6
PEI
1.2
2.0 x 106
2.1 x 108 4.4 x 106
5.2
30a
6
PEI
0.6
2.0 x 10
3.7 x 108 3.4 x 108
185.0
27
6
7
7
2.0 x 10
5.3 x 10
4.8 x 10
26.5
PEI
0.5
2.0 x 106
5.6 x 106 5.6 x 106
2.8
29a
6
7
7
PEI
1.0
1.0 x 10
1.7 x 10
1.7 x 10
17.0
31
PEI
2.0
1.0 x 106
1.2 x 107 6.0 x 106
12.0
32
7
7
5
PEI
1.9
2.0 x 10
1.5 x 10
3.95 x 10
0.8
33
a
Specific productivities in units of pg of Gag-GFP polyprotein per mL, ug plasmid, or
cell.
Data are ordered by date of publication.
Italicized values were derived from reported transfection information and titers.
PEI = Polyethylenimine.

Objectives
We hypothesized that higher volumetric titers of lentivirus due to transfection at
higher cell densities are supported by the ThermoFisher LV-MAX Production System
using its proprietary culture medium, cationic lipid transfection reagent, transfection
supplement, and transfection enhancer. The following research objectives were
established to test this hypothesis:
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1. Culture HEK293 cells in shake flasks to high cell densities using chemicallydefined, serum-free medium.
2. Efficiently transfect HEK293 cells at high cell densities using lipofection.
3. Monitor variables in the transfection process that impact reproducibility.
4. Determine lentiviral vector titer and compare with previous reports in literature.
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CHAPTER 2
METHODS
Overview
Lentiviral vectors were produced by transient transfection of HEK packaging cells
in shake flasks. A schematic overview of the processes used for producing and
quantifying the vectors is portrayed in Figure 3. Further details are provided in
subsequent sections.

Figure 3. Schematic overview of lentiviral vector production and quantification.
Created with BioRender.com

Preparation of Backbone Plasmid
The backbone plasmid, pLJM1-EGFP, was a gift from David Sabatini (Addgene
plasmid # 19319; http://n2t.net/addgene:19319 ; RRID:Addgene_19319). This plasmid is
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a third-generation high-copy plasmid containing genes for enhanced Green Fluorescent
Protein (EGFP), puromycin resistance, and ampicillin resistance (Figure 11 – Appendix
A).
The pLJM1-EGFP backbone plasmid was expanded in chemically competent
DH5α cells generously provided by the Charles Miller Synthetic Biology Laboratory
(Utah State University). All procedures associated with backbone plasmid expansion
were performed in a class II biosafety cabinet in a biosafety level 1 laboratory.
Ampicillin and antibiotic-free LB-agar plates and TB broth were prepared
according to Elbing and Brent.34 Prior to the transformation procedure, LB plates were
warmed in an incubator to 37 °C, and the chemically competent DH5α cells were thawed
on ice (20-30 minutes). Stock pLJM1-EGFP (100 ng/uL) was diluted 100-fold in sterile
nuclease-free water (Invitrogen, Grand Island, NY). 5 uL of diluted plasmid (1 ng/uL)
was pipetted into 50 uL of competent E. coli in a microcentrifuge tube, and the tube was
gently flicked to mix. A negative control was similarly prepared by replacing plasmid
with 5 uL of nuclease free water; subsequent steps were performed to both mixtures.
Plasmid was transformed into cells through heat shock by incubation in a 42 °C water
bath for 45 sec., followed by immediate placement on ice for 2 min. 500 uL S.O.C.
medium (Invitrogen 15544-034) was added to the cells, which were incubated for 15 min.
at 37 °C in a shaking incubator at 250 RPM. 50 uL of transformed cells were pipetted
onto ampicillin and ampicillin-free LB-agar plates and spread with a sterile spreader.
Plates were inverted and incubated overnight at 37 °C.
Transformed colonies were present on the ampicillin plate while no colonies were
visible on the negative control ampicillin plate, indicating successful transformation of
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the backbone plasmid. A single transformed colony was selected from the ampicillin
plate with a flame-sterilized wire loop and used to inoculate 40 mL TB broth in an
autoclaved 125-mL glass shake flask. 40 uL ampicillin (100 mg/mL) was pipetted into
the medium, and flasks were covered with autoclaved aluminum foil and placed in a
shaking incubator (37 °C, 250 RPM) for 16 – 18 hours. Plasmid was extracted from
bacterial fermentations by using a plasmid extraction kit.
Plasmid Extraction
High purity plasmid preparations were extracted from 100 mL bacterial
fermentations (OD600 3.0-4.0) using the PureLink Expi Endotoxin-Free Maxi Plasmid
Purification Kit (Thermo Fisher A31217) per the manufacturer’s instructions (centrifuge
method) with some optimized adjustments: Terrific broth (TB) was used to culture bacteria
to maximize plasmid production. The harvested cell pellet was resuspended by inversion
rather than by vortexing. A sample-free duplicate was prepared as a DNA-binding column
pre-wash by combining the resuspension, lysis, precipitation, and endotoxin removal
buffers in the same ratios used for the harvested cell pellet. The pre-wash was passed
through a clean lysate clarification column, then added to the DNA-binding column and
pulse-centrifuged until the entire column was wetted. Clarified bacterial lysate was loaded
onto the column when only a sliver of pre-wash remained above the column header. The
binding column was washed twice after loading with lysate. DNA was eluted by first
centrifuging at 500 x g for 1 min, followed by 2,000 x g for 2 min. After elution, 0.7 times
the sample volume of isopropanol was added and the sample was partitioned into
microcentrifuge tubes, then centrifuged at 16,000 x g for 30 min. Samples were chilled
overnight at -20 °C to enhance nucleic acid precipitation. The next day, samples were re-
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centrifuged for 1 min. The supernatant was carefully discarded by micropipette. Pellets
were washed with 70% ice-cold ethanol then re-centrifuged. The supernatant was carefully
discarded, and nucleic acid pellets were air dried for 10 minutes. Pellets were resuspended
in 10 mM tris buffer (pH 8.0)
Total DNA yields and purities were approximated by measuring sample absorbance
at 260 and 280 nm. Backbone plasmid concentration was determined by quantitative PCR
as described below.
After initial transformation, glycerol stocks of the transformed E. coli were
prepared by adding 500 uL of overnight E. coli culture to 500 uL of 50 % glycerol solution
(50% glycerol and 50% nuclease-free water). Glycerol stocks were stored at – 80 ᵒC.
Ampicillin plates with transformed E. coli were stored at 4 °C for up to 1 month and used
for repeated preparations of backbone plasmid. Plates were discarded after 1 month, and
new plates were prepared by partially thawing glycerol stocks and streaking cells onto the
plates with a flame-sterilized wire inoculating loop.
HEK Cell Culture
All cell culture manipulations were conducted in a class II biosafety cabinet in a
biosafety level 2 laboratory. Vials of cryopreserved HEK293F Viral Production Cells (Life
Technologies, Grand Island, NY) were thawed in a water bath at 37 °C, then transferred
by pipet into chemically defined, serum- and protein-free medium (LV-MAXTM
Production Medium, Life Technologies). Cells were grown in 125-mL single-use PETG
shake flasks (Thermo Fisher Scientific, USA, Cat. No. 41150125) in a high-humidity
incubator set to 37 °C and 8% CO2. Flasks were agitated on a 1.9 cm orbital shaker (Thermo
Fisher Scientific, Cat. No. 88881103) at 110 rpm in the incubator. Viable cell density and
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culture viability were determined by counting cells stained with 0.4% Trypan Blue (3- to
5-fold dilution) on a hemocytometer (200x magnification under inverted microscope). Cell
density, viability, and growth rate were routinely determined in preparation for transfection
experiments.
Cell culture was maintained according to the LV-MAX User Manual. Briefly, cells
were counted every 3 – 5 days to determine cell density. Cells were typically passaged
when a density of 3.5 – 5.5 x 106 cells/mL was reached by either directly diluting the culture
with fresh medium, or by transferring cells to a new flask with fresh medium. Cells were
cultured in 25 to 45 mL of medium and typically seeded at densities between 0.35 – 0.55
x 106 cells/mL. Cultures were discarded after approximately 40 passages.
Cells were regularly cryopreserved to maintain adequate stocks for viral vector
production. Cultures that reached high cell densities (>3.5 x 106 cells/mL), exponential
growth rates (doubling time approximately 26 – 32 hours), and high viabilities (>95%)
were used for preservation. Cultures were centrifuged at 100 x g for 5 min. in a 50 mL
centrifuge tube. Culture supernatants were removed by serological pipet, then cell pellets
were resuspended by gentle inversion in sterile cryopreservation medium (10% v/v DMSO
in LV-MAX production medium, 0.22 uM filtered) to a final density of 1 x 107 cells/mL.
1 mL aliquots were transferred to cryovials and frozen at – 80 °C for one day, then
transferred to liquid nitrogen vapor space for long-term storage.
Viral Production by Transient Transfection
HEK293F Viral Production cells were transfected with the pLJM1-EGFP
backbone plasmid expanded in E. coli, and packaging plasmids provided in the LV-MAX
transfection kit (Thermo Fisher, A43237). Transfection was performed based on the LV-
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MAX User Manual. Briefly, cells were cultured 3-6 days to a high density in LV-MAX
Production Medium and diluted to 3.5-4.0 x 106 cells/mL with fresh medium at least 24
hours prior to transfection. The day of transfection, cell densities of several cultures were
determined, and 2-4 cultures were combined at various ratios to achieve mixed densities
of 5.0 – 7.0 x 106 cells/mL. Mixed cultures were then diluted with fresh medium in a new
flask to 25.5 mL at a density of 4.7 x 106 cells/mL. 1.5 mL LV-MAX Supplement was
added to diluted cultures, which were then returned to the orbital shaker in the incubator.
Packaging and backbone plasmids were combined at a ratio of 3:5 in 1.5 mL OptiMEM I
Reduced Serum Medium. Total specific plasmid mass used was 1.0 ug/106 cells to be
transfected. 180 uL LV-MAX Transfection reagent (6 uL/mL) was mixed into 1.5 mL
OptiMEM I Reduced Serum Medium and incubated at room temperature for 1 minute.
The combined DNA was then pipet mixed with the transfection reagent and incubated for
at least 10 minutes at room temperature to facilitate complexation of the plasmids and the
lipid reagent. The DNA-lipid complex was then pipet mixed with the previously prepared
flask of cells. Transfected cell cultures were then transferred to a separate BSL II lab to
avoid cross-contamination of LVVs with non-transfected cell culture. The transfected
cultures were placed on a 19-mm orbital shaker in an incubator under the same operating
conditions as described previously. Two negative control groups were also prepared
during each transfection experiment by transfecting with either packaging or backbone
plasmids only. At between 5 and 14 hours post transfection (hpt), 1.2 mL of LV-MAX
Enhancer was pipet mixed into each culture. At 46 – 49 hpt, the transfected cultures were
harvested, and transfection efficiencies and LVV titers were determined.
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Determination of Transfection Efficiency by GFP Expression
Expression of Enhanced Green Fluorescent Protein (EGFP) in transfected cells
was determined at approximately 48 hpt to assess transfection efficiency. A 50 uL sample
of transfected cell culture was diluted 1:10 in Hoechst 33342 nuclear stain (5 ug/mL) and
incubated at room temperature for 5 min. Hoechst 33342 is a cell-permeant stain that has
peak excitation and emission wavelengths at 350 and 461 nm, respectively. The blue
emission can be detected through a DAPI filter. Stained cells were loaded into EVE
disposable counting slides (NanEnTek, EVS-050) and imaged at 40x magnification using
the Cytation 1 multi-mode plate reader (Biotek, VT, USA). Two randomly selected areas
of each cell sample were imaged using the Brightfield detection channel as well as
through DAPI and GFP filters. Camera exposure settings are listed in Table 2 below.

Table 2. Cytation 1 camera exposure settings for imaging of transfected cells.
Parameter
LED Intensity
Integration
Time (ms)
Camera Gain

Brightfield
4

DAPI
8

GFP
10

34

1000

800

1

1

1

Cellular analysis was conducted using the Gen5 software to approximate total cell
counts (DAPI detection channel) and GFP-expressing cell counts (GFP detection
channel). Detection threshold was set to 13,000 intensity, primary edge objects were
excluded from the count, and object size was set to 10-75 uM. Transfection efficiency
was determined as the ratio of GFP-expressing cells to the total number of cells present in
a sample image.
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Determination of Lentiviral Vector Titer by RT-qPCR
RNA was extracted from transfected cell culture supernatants to approximate nonfunctional viral titer through reverse-transcription quantitative PCR (RT-qPCR).
RNA Extraction
The RNA extraction protocol was an adaption of Roper and VanRenslaar (in
preparation), which provides a method of extracting viral RNA from natural
environments by spin column extraction. Briefly, at approximately 48 hpt transfected cell
cultures were centrifuged at 4696 x g for 10 minutes in a swinging bucket centrifuge at 4
ᵒC. Transfected cell culture supernatants were transferred by pipet into 50 mL conical
tubes containing 7.0 g NaCl and 300 uL TE Buffer (1 M Tris, 0.1 M EDTA, pH 7.2). The
total volume of each supernatant was recorded prior to addition to the salt tubes
(approximately 30 mL). Salinated supernatants were inverted to mix, then incubated in a
60 ᵒC water bath for 1 hour to inactivate lentiviral particles. Samples were inverted again
at 30, 45, and 60 minutes into inactivation to ensure total dissolution of the salt.
Following lentiviral inactivation, supernatant samples were re-centrifuged to pellet
residual debris. 7-10 mL of the inactivated supernatant was transferred to a new tube, and
100% ethanol was added dropwise while swirling to a concentration of 35% v/v. Samples
were gently inverted 5-10x to mix.
A daisy chain assembly of two RNA-binding spin columns was connected to a
vacuum manifold. 4 mL pre-wash was loaded into the column reservoir to prewet the
spin columns. 5-10 mL of the ethanol containing sample was loaded into the reservoir
before the column dried free of prewash. Reservoirs were covered with parafilm after
adding sample to prevent ethanol evaporation. 2 mL of Wash Buffer 1 was added to the
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column before it was dried, then 3 mL of Wash Buffer 2 (WB2) was similarly added, but
the column was vacuumed dry. The primary spin column loaded with RNA was removed
from the daisy chain assembly and inserted into a collection tube, then centrifuged at
10,000 x g for 2 minutes to elute residual WB2. The collection tube was discarded, and
the spin column was heated uncapped in a culinary forced-convection oven at 160 ᵒF for
60 seconds to evaporate residual ethanol. Spin columns were placed in sterile elution
tubes, then 50 uL of 10 mM Tris (pH 8.0) prewarmed to 70 ᵒC in a water bath was added
to the column. The column was centrifuged for 1 minute at 0.5 x g to allow absorption
but not elution of tris through the column. The column was reheated in the convection
oven then centrifuged at 10,000 x g for 2 minutes to elute and collect the RNA. A second
elution was pooled with the first by adding 100 uL of Tris to the column and repeating
the centrifugation and heating steps. Total RNA concentrations in each sample were
estimated by spectrophotometry.
Reverse-transcription qPCR
LVV gene copies in transfected cell cultures were quantified via RT-qPCR on a
QuantStudio 3 PCR machine (Applied Biosystems). RNA extracts from culture
supernatants were treated with DNase (Fisher Scientific, EN0525) according to
manufacturer recommendations to degrade residual plasmid DNA carried over from the
transfection process. The qScript One-Step SYBR Green RT-qPCR kit (Quantabio,
95089-200) was used as the reaction master mix. Lyophilized primers were ordered from
Integrated DNA Technologies and were rehydrated in nuclease free water to a 100-uM
stock concentration. Working concentration of primers in the master mix was 0.2 uM.
Primer sequences were those identified by Butler et al. located in the 5’ LTR of the viral
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genome,35 and had the following positions and sequences on the pLJM1-EGFP backbone
plasmid: Forward primer (103–122 bp) TGTGTGCCCGTCTGTTGTGT; Reverse primer
(245–226 bp) GAGTCCTGCGTCGAGAGAGC. Total qPCR reaction volume contained
4.0 uL of DNase-treated RNA (diluted to approximately 1 ng/uL total RNA in 10 mM
Tris, pH 8.0) and 6.0 uL of master mix prepared according to manufacturer
recommendations. Non-template controls (NTCs) were prepared by substituting RNA
samples with 10 mM Tris. Stock of pLJM1-EGFP plasmid (10 ng/uL) was serially
diluted in 10 mM Tris from 1.2 ng/uL to 7.5 x 10-6 ng/uL to contribute five known
concentrations of a calibration curve. The PCR reaction was as follows: Reverse
Transcription stage – 10 min at 50 ᵒC; PCR Stage – 40 cycles of 10 sec at 95 ᵒC followed
by 30 sec at 60 ᵒC; Melt Curve Stage – 60 ᵒC increased to 95 ᵒC at 0.15 ᵒC/s.
Plasmid copy number was calculated from plasmid mass based on length,
assuming a molecular weight of 660 Da for dsDNA (see Equation 1 in Appendix A).
Viral gene copies were considered analogous to plasmid copies such that LVV gene
copies in a sample were determined by direct comparison to the quantification cycles of
the backbone plasmid calibration curve. This PCR reaction method was also used to
quantify backbone plasmid extracts.
Statistical Analysis
One-way ANOVA with Tukey’s post hoc analysis was used to identify
statistically significant relationships (p-value <0.05). Analysis was performed using SAS
OnDemand for Academics.
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CHAPTER 3
RESULTS
Determination of LVV Titer and Transfection Efficiency
Measurement of vector genomes in transfected culture supernatants through RTqPCR provides a simple and rapid approach to quantification of LVV titer.36 In our
experiments, viral RNA was extracted from vector supernatants 48 hours post
transfection (hpt) and quantified by RT-qPCR. A known concentration of backbone
plasmid was used as the standard for the PCR assay and provided a reliable calibration
curve across all experiments. Figure 4 shows the average quantification cycles (Cq) for
the initial template concentrations in the calibration curve. Due to the exponential nature
of PCR amplification, the base 10 logarithms of the template concentrations are graphed
to linearize the calibration curve.
Amplification efficiency in a PCR reaction provides a measure of exponential
replication, where 100% efficiency represents a 2-fold increase in nucleic acid
concentration per cycle.37 The average amplification efficiency across 10 PCR assays was
91.55%. Amplification efficiency was calculated using Equation 2 (Appendix A).
No degradation of the plasmid standard was observed over the duration of the
transfection experiments. Non-template controls (NTCs) were used to detect PCR
contamination and primer dimers. Cq ≥ 30.00 for NTCs was considered the limit for
accepting assay data.

21

Quantification Cycle (Cq)

25.00

20.00

15.00
y = -3.54x + 5.54
R² = 0.998

10.00

5.00

0.00
-6.00

-5.00

-4.00

-3.00

-2.00

-1.00

0.00

1.00

Log DNA Concentration (ng/uL)

Figure 4. Average quantification cycles (Cq) for pLJM1-EGFP backbone plasmid
calibration curve. Values represent the average of 10 RT-qPCR experiments with Cq
standard deviations indicated as y-axis error bars. Average amplification efficiency was
91.55%.

The backbone used for this study was a simple reporter plasmid with a Green
Fluorescent Protein (GFP) transgene. For some experiments, transfection efficiency was
approximated by comparing GFP-expressing to total cell densities at 48 hpt. Measuring
the percentage of GFP-expressing cells relative to total cells post-transfection, such as by
flow cytometry or fluorescent microscopy, is commonly used to approximate transfection
efficiency in LVV production.38,39 Transfected cell culture samples were stained with
Hoescht 33342 nuclear stain, loaded into a counting chamber, and viewed through DAPI
and GFP filters in a Cytation 1 multi-mode imager. Gen5 software was used to
automatically enumerate total cells (DAPI filter) and GFP-expressing cells (GFP filter) in
a sample. Cell density was calculated by dividing the number of total or GFP-expressing
cells in a sample by the depth of the chamber and the area of the image. The fluorescent
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imager and software approximated cell density within 10% of the standard Trypan Blue
exclusion assay and a hemocytometer (Figure 5).

Cytation1 Cell Density (106 cells/mL)
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Figure 5. Comparison of cell densities determined by fluorescent microscopy and
software to standard hemocytometer method. Duplicate samples of cell culture were
stained with Hoechst 33342 (cell membrane-permeant) and SYTOX Green (cell
membrane-impermeant) fluorescent nuclear stains, then imaged using a Cytation 1 multimode imager through DAPI and GFP filters, respectively. Gen5 software was used to
generate total cells counts from DAPI images and dead cell counts from GFP images.
Viable cell count was taken as the difference between total and dead cell counts. Cell
counts were converted to density by dividing by the volume of the counting chamber.
Error bars represent the standard deviation between cell counts for 6 images (3 images
per cell culture sample). Total and viable cell densities were compared to densities
determined by Trypan Blue exclusion assay with a hemocytometer. A line y=x
representing perfect agreement between methods is also graphed for reference.

In addition to co-transfection of backbone and packaging plasmids into suspended
culture HEK cells, control groups were included that were transfected with either
backbone or packaging plasmids alone. Transgene expression on the backbone plasmid is
controlled by the CMV promoter, which allows for constitutive expression in mammalian
cells and high levels of expression specifically in HEK cell lines.40 Consequently, GFP
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expression was observed in cultures transfected with both backbone and packaging
plasmids and cultures transfected with backbone plasmid only; no GFP expression was
observed in groups transfected with packaging plasmid only (Figure 6). Slightly higher
levels of GFP expression were observed for cultures transfected with both packaging and
backbone plasmids over cultures containing backbone plasmid only. This suggests
functional viral particles were produced in the cultures transfected with both plasmids,
resulting in the infection and subsequent transgene expression of some non-transfected
cells.

Figure 6. Expression of enhanced green fluorescent protein (GFP) in transfected
HEK cells 48 hours post transfection. Images depict cultures transfected with (A)
packaging and backbone plasmids, (B) backbone plasmid only, or (C) packaging
plasmids only. Reduced levels of GFP expressing cells are identified in (B) (7.82%)
compared to (A) (9.12%), while no expression is identified in sample (C). Cells were
imaged using a Cytation 1 multi-mode imager at 40x magnification in Brightfield mode
(upper images), DAPI mode (not shown), and GFP mode (lower images). All cultures
used in this experiment were split from a mixed culture at 6.8 x 106 cells/mL prior to
transfection.
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LVV Titer Increases with Cell Density Pre-transfection
To examine the effect of cell density prior to transfection on LVV titer and
transfection efficiency, cells were cultured to a high cell density, pooled with other flasks
to provide homogeneous cultures, then diluted with fresh medium to 4.7 x 106 cells/mL to
begin transfection.
Figure 7A shows viable cell densities (VCDs) prior to dilution for transfection
and associated LVV titers 48 hpt of seven separate transfections. Up to 6.0 x 106
cells/mL, there was a positive correlation between increasing cell density and increasing
LVV titer, with a 6.3-fold increase in LVV titer as VCD increased from approximately
5.0 to 6.0 x 106 cells/mL. Transfection experiments with statistically significant
differences in LVV titer are indicated by brackets with the associated p-value. Above 6.0
x 106 cells/mL, LVV titer began to decline. Prior to transfection all cultures used
maintained viabilities greater than 90% at the high cell densities. LVV gene copies
collected 48 hpt per viable cell at the start of transfection increased from approximately
7.3 to 154.1 as cell density pre-transfection increased from 5.1 to 6.0 x 106 cells/mL.

25
*p = 0.0134

A

*p = 0.0078
*p = 0.0375

9.0
8.0

96.9%

7.0
6.0
5.0

94.0%

4.0
3.0

95.8%

2.0

96.2%

92.2%
92.9%

1.0
0.0

94.9%

5.0

5.2

5.4

5.6

5.8

6.0

6.2

Viable Cell Density Pre-Transfection (
1.6

GFP Cell Density (106 cells/mL)

B

6.4

106

6.6

6.8

7.0

cells/mL)
25%

GFP Density

1.4

% GFP Expression

20%

1.2
1.0

15%

0.8
10%

0.6
0.4

5%

% GFP Expressing Cells

108 LVV Gene Copies/mL

10.0

0.2
0.0

5.0

5.2

5.4

5.6

5.8

6.0

6.2

6.4

6.6

6.8

7.0

0%

Viable Cell Density Pre-Transfection (106 cells/mL)

Figure 7. Relationship between viable cell density (VCD) prior to transfection to (A)
LVV titer and (B) transfection efficiency. X-axis cell densities represent the combined
VCD of 2 to 4 cell cultures mixed on the day of transfection before being diluted with
fresh growth medium to the final density at which cells were transfected (4.7 x 106
cells/mL). (A) Percent viabilities for the combined cultures are reported adjacent to data
markers. Vertical error bars represent the standard deviation of technical replicates from
qPCR. Asterisks and brackets indicate significantly different titers and their associated pvalues for VCDs less than 6.0 x 106 cells/mL. (B) % GFP expression was determined as
the ratio of GFP expressing cells to total cells in a sample 48 hpt. Vertical error bars
represent the standard deviation of duplicate images from the sample of a given cell
culture.
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Transfection of HEK cells cultured to high cell densities prior to transfection can
increase volumetric expression of the transgene but may not improve transfection
efficiency. Of the experiments where GFP-expressing and total cell densities were
measured 48 hpt, the highest measured transfection efficiency was 19.6% from a culture
with a pre-transfection density of 5.7 x 106 cells/mL (Figure 7B). The highest GFPexpressing cell density observed was 1.3 x 106 cells/mL from a culture with a pretransfection density of 6.6 x 106 cells/mL. The density of GFP-expressing cells increases
with increasing VCD pre-transfection up to about 6.6 x 106 cells/mL and then declines,
suggesting that volumetric productivity as measured by GFP expression has a positive
relationship with VCD pre-transfection up to 6.6 x 106 cells/mL. Percent GFP expression,
however, decreases slightly at pre-transfection VCDs greater than approximately 6.0 x
106, indicative of lower transfection efficiency.
A comparison of cell densities pre-transfection to total cell densities 48 hpt is
provided in Table 3. Note that viable density post-transfection was not determined, as the
method for determining VCD using the fluorescent microscope required use of a greenfluorescent nuclear stain, which was indistinguishable from cells expressing GFP protein.
Cells were diluted to 4.7 x 106 cells/mL to initiate transfection. After 48 hours, total cell
densities had recovered to ±8.0% of their value before being diluted for transfection.
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Table 3. Comparison of total cell densities prior to transfection to total cell densities
48 hours post-transfection.
VCD Pre-tfxn TCD Pre-tfxn TCD 48 hpt
% Difference
(106 cells/mL) (106 cells/mL) (106 cells/mL in TCDs
5.1
5.5
5.9
5.9
5.7
6.1
5.9
-3.9
6.6
6.9
7.5
8.0
6.8
7.2
7.0
-2.3
Tfx = Transfection. VCD = Viable Cell Density. TCD = Total Cell Density.
Data are arranged by increasing VCD pre-transfection.

Specific LVV Productivity Increases with Cell Density Pre-transfection
Comparison of lentiviral vector titration methods has shown that measurement of
viral gene copies in transfected culture supernatants by RT-qPCR overestimates
functional viral titers.36 The ratio of viral gene copies to transducing units ranges from
approximately 102 to 104.33,36,41,42 Our method of extracting RNA from vector
supernatants includes a heat incubation step to inactivate viral particles, binding of RNA
to spin columns, treatment of RNA preparations with DNase, and subsequent enzyme
inactivation by both heating and EDTA addition prior to PCR. These processing steps
diminish the risk of residual plasmid DNA from transfection contaminating the vector
RNA preparations and inflating RNA titers. Additionally, our use of a plasmid standard
for PCR likely underestimates viral RNA titers due to inherent inefficiencies of the
reverse transcription step.42 If the reverse transcription step isn’t 100% efficient, less
complimentary DNA will be present at the start of the PCR amplification cycles than
what corresponds to the LVV RNA. Since the standard was plasmid, it would not require
reverse transcription, so all plasmid present in the sample will presumably be amplified,
thus underestimating RNA in the sample. Therefore, for the purpose of comparing our
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results to those of others, we will assume a conservative ratio of 102 viral gene copies to
an equivalent transducing unit (TU).
Specific volumetric, biomass, and plasmid productivities were calculated from
equivalent TUs (see Equations 3-5 in Appendix A). Specific volumetric productivity is
the ratio of TUs 48 hpt to the total culture volume at the time of transfection. Specific
biomass productivity is the ratio of TUs 48 hpt to the number of viable cells present at the
start of transfection. Specific plasmid productivity is the ratio of TUs 48 hpt to the mass
of plasmid used to perform the transfection.
While the total volume and number of cells transfected were maintained between
experiments, specific plasmid productivity increased from 7.3 x 106 to 1.5 x 108 viral
gene copies per microgram of plasmid. This is equivalent to 0.73 x 105 TU/ug plasmid to
a maximum of 1.5 x 106 TU/ug plasmid as the cell density pre-transfection increased
from ~5.0 x 106 cells/mL to 6.0 x 106 cells/mL (Figure 8A). The important implication is
that specific plasmid productivity can be increased 20-fold by simply culturing cells to
higher densities (in our case up to 6.0 x 106 cells/mL) prior to diluting to the final density
for transfection with fresh medium. Because volume and cell density at transfection were
held constant, increases in specific biomass and volumetric productivities were
proportional to specific plasmid productivity.
The highest volumetric productivity we observed (7.3 x 106 TU/mL) was similar
to or higher than several previous reports, while specific plasmid and specific biomass
productivities 1.5 x 106 TU/ug plasmid and 1.5 TU/cell, respectively, were generally
lower (Figure 8B).
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Figure 8. Comparison of Specific LVV Productivities. (A) Results of the present work
compared to cell density pre-transfection. Transducing units were approximated from
vector RNA titer, and specific volumetric, biomass, and plasmid productivities were
calculated. (B) Specific productivities from studies where LVV production was
performed in shake flasks. Productivities are calculated on the same basis as described in
Equations 3-5 of Appendix A, except that Tang et al., Segura et al., and Gelinas et al.
measured LVV titer 72 hpt instead of 48 hpt.20,24,32 Optimized conditions are reported
(see Table 1) and organized left to right by decreasing TU/mL. Studies on the production
of lentivirus-like particles are excluded from this comparison.
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Passage Routine Pre-transfection Affects LVV Titer
It is understood that cell physiological state can significantly influence
transfection efficiency. Specifically, highest levels of transgene expression are strongly
correlated with active cell division by cationic lipid-mediated transfection43 as well as by
polymer-mediated transfection.44 To elucidate the relationship between high cell density
and LVV titer, cell growth rate leading up to transfection was evaluated for all cultures
used in transfection.
During routine cell culture, when cells are introduced to fresh growth medium a
lag in growth rate is temporarily experienced as the cells acclimate to the new medium.
We observed that the growth rate for HEK293 cells typically decreased to between 0.25
and 0.50 population doublings per day within 24 hours of dilution with fresh medium
(data not shown) but recovered to maximum growth rates of 0.80 to 0.90 population
doublings per day by day 3 following subculture. Figure 9A shows the velocity and
VCDs of a culture used for a transfection where time between passages did not exceed 4
days. One day prior to transfection, the culture was diluted with fresh medium to a
density of 4.0 x 106 cells/mL. On the day of transfection, VCD and growth rate were
determined, then the culture was pooled with other cultures maintained on similar
passaging schedules. The VCD of the combined cell cultures was 5.6 x 106 cells/mL prior
to diluting with fresh medium for transfection. The pattern of velocity seen in this
example was typical of other cultures whose combined density was less than 6.0 x 106
cells/mL pre-transfection. Notably, cell growth rate declined on the day of transfection in
cultures partially diluted with fresh medium one day pre-transfection, similar to the lag
cells experienced during routine passaging.
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Figure 9. Viable cell density (VCD) and velocity of cell culture prior to transfection.
Separate flasks of cells were passaged every three to five days, then diluted with fresh
medium to a density between 3.0-4.0 x 106 cells/mL either (A) one day or (B) two days
prior to transfection. On the day of transfection, cell cultures were mixed then diluted
with fresh medium to the final density for transfection (4.7 x 106 cells/mL). Mixed cell
densities on the day of transfection were (A) 5.6 x 106 and (B) 6.6 x 106 cells/mL. The
far-right data label denotes the dilution factor from combining cell cultures, the dilution
factor from addition of fresh medium to the combined cultures, and the percent the
graphed cell line contributed to the total transfection volume.
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In some instances, a culture was grown for more than 4 days without the addition
of fresh medium. When this occurred, there was an immediate decline in growth velocity.
Figure 9B shows an example of the velocity and VCDs of a culture used for transfection
where the time between passages exceeded 4 days. The culture experienced a slight
decline in VCD on the fifth day since passaging and was diluted with fresh medium. By
the day of transfection, the growth rate of the culture had significantly recovered to 0.64
population doublings per day. This incidence of extended passage period before
transfection occurred in cell cultures used for both transfection experiments where the
combined VCD pre-transfection was greater than 6.0 x 106 cells/mL.
Although velocities recovered to higher levels by the day of transfection, it is
possible that residual effects of the extended culturing contributed to the lower LVV
titers. Alternatively, in both transfection experiments where the combined VCD pretransfection surpassed 6.0 x 106 cells/mL, the cells were introduced to fresh medium two
days prior to transfection, whereas in pooled cultures below 6.0 x 106 cells/mL on the day
of transfection, fresh medium was introduced only a day before transfection. It is possible
that although cells diluted 1 day prior to transfection were still experiencing lag in growth
rates, the more recent introduction of medium provided sufficient nutrients to keep the
cells in a state of active division through transfection. Cultures diluted more than 1 day
prior to transfection may have reached the maximum density the growth medium could
sustain without addition of nutrients by day 0. In either case, inconsistencies in the
passaging routine leading up to transfection negatively influenced LVV titer.
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Results Summary
The results of seven transfection experiments have been presented with emphasis
on the effect of cell density pre-transfection and passage routine leading up to
transfection on LVV titer and specific LVV productivity. We observed increases in LVV
titer and specific LVV productivity associated with increases in cell density pretransfection up to 6.0 x 106 cells/mL. We speculate that reductions in LVV titer and
specific LVV productivity for pre-transfection densities greater than 6.0 x 106 cells/mL
can be attributed to variations in passage routine several days prior to transfection.
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CHAPTER 4
DISCUSSION
Challenges to the scaleup of lentiviral vector production by transient transfection
include limitations to specific plasmid productivity, limitations to transfection efficiency
at high cell density, and significant titer variability between production batches. The
results of the present study can help overcome these challenges and will be discussed in
the context of relevant findings from prior literature at three hierarchal scales: the
cellular, the process, and the manufacturing scales.
Cellular Scale
Expression of transgenes following transfection is dependent on successful entry
of the gene vector into the cell nucleus. Gene vectors, such as plasmids (pDNA), can
enter the nucleus following mitotic dissociation of the nuclear membrane or, to a lesser
degree, by import through nuclear pore complexes.26 Higher transfection efficiencies are
thus generally associated with active cell division when the disassembly of the nuclear
envelope exposes gene vectors to the nuclear space. Following cytokinesis and
reformation of the nuclear envelope, cytosolic pDNA can become localized in the
nucleus alongside cell chromosomes.26 The successful entry of pDNA into the nucleus is
the most significant driver of transgene expression when considering other potential
factors such as DNA topology, 31,45 DNA purification method,46 concentration of pDNA
in the cytoplasm,43 or the type of transfection reagent used.44 While some transiently
transfected pDNA may enter the nucleus during interphase, as much as 83% of transgene
expression from lipofection is associated with nuclear entry following mitosis.47
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Interestingly, Kirchenbuechler et al. found that in HeLa cells transiently transfected by
lipofection, equivalent levels of transgene expression can occur in cells entering mitosis
up to 30 hours post-transfection as in those entering mitosis immediately following the
addition of the transfection mixture.47 By extension, if a given cell divides within 30
hours post-transfection, there is a possibility for the DNA lipoplexes to survive the
residence time in the cytoplasm and be enclosed in the nucleus during the next mitotic
event. Consequently, methods for maintaining cells in an actively dividing state
following transient transfection can significantly increase levels of transgene expression.
In the present study, levels of GFP expression and LVV genomic RNA increased
as cell densities prior to transfection increased from approximately 5.0 to 6.0 x 106
cells/mL. Given that all packaging cell cultures were diluted to the same density at the
start of transfection, it is possible that increases in the density of pre-transfection cultures
contributed to increased rates of cellular division post-transfection, thus improving LVV
titer.
At a pre-transfection cell density of 6.0 x 106 cells/mL, we attained a LVV gene
copy volumetric productivity approximately equivalent to 7.3 x 106 TU/mL. Of the
previous studies where lentiviral vectors were produced in shake flasks, our results were
3 to 12-fold higher than two studies,20,24 within 2.5-fold of four studies,19,31–33 and
approximately 50-fold lower than one study.27 Gélinas et al. reported the lowest lentivirus
titer, likely because their vector was pseudotyped with Sendai virus F/HN envelope
proteins, which has been shown to reduce LVV titers by 20 to 40-fold compared to
vectors pseudotyped with VSV-G.20,48 Segura et al. reported the second lowest titer.
Theirs was the first demonstration of LVV production in suspension cell culture format
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and set the stage on which future studies built. Some studies reported volumetric
productivities greater than our findings. In particular, Bauler et al. achieved specific
productivities that were at a minimum 22-fold higher, and at a maximum 617-fold higher
than previous studies.27 They developed from HEK293T cells a suspension-adapted cell
line that was conditioned to achieve fast growth rates and high cell densities in the
absence of serum. Their process of converting adherent cells to grow in suspension may
have selected for high LVV-producing cells. Additionally, they incorporated a complete
medium replacement 24 hpt, which replenished nutrients and likely reduced cytotoxicity
by removal of residual PEI-DNA polyplexes. While complete medium replacement posttransfection significantly increased LVV titer, this technique is not scalable and reduces
the true volumetric titer when considering total medium used for post-transfection cell
cultivation. When transfected cultures were diluted with an equal volume of fresh
medium 24 hpt rather than complete exchange, Bauler et al. reported a 7-fold decrease in
volumetric titer.
To date, several other studies on the optimization of lentiviral vector production
have mainly addressed changing nutrient utilization of transfected cells by total
replacement of the bulk medium prior to transfection,30 after transfection,20,28 or both.19,33
Additionally, Gélinas et al. investigated the effect of supplementation by various lipid
and peptide mixtures on LVV titers, but did not observe significant improvements.20 The
change in nutritional requirement of transfected cells for lentiviral vector production
post-transfection has not been fully defined in literature, and should be the subject of
future studies.
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Those studies which did not use medium replacement are summarized in Table 4
and compared to our highest results. The average volumetric productivity of these three
most comparable studies was 1.0 x 107 TU/mL. Our results are within 70% of this
average.

Table 4. Volumetric productivities of lentiviral vectors (LVV) produced in shake
flasks by transient transfection of HEK cell derivatives without medium
replacement.
Plasmid
Transfection
TU/ug
Transfection
(ug) per
Cell Density TU/mL
TU/cell Ref.
plasmid
Method
106 Cells
(cells/mL)
PEI
1.0
1.0 x 106
2.3 x 106 2.3 x 106
2.3
24
6
6
6
LP
1.0
4.7 x 10
7.3 x 10
1.5 x 10
1.5
PS
PEI
2.0
1.0 x 106
1.2 x 107 6.0 x 106
12.0
32
6
7
7
PEI
1.0
1.0 x 10
1.7 x 10
1.7 x 10
17.0
31
Italicized values were derived from reported transfection information and titers.
Data are reported by increasing volumetric productivity (TU/mL).
PEI = Polyethylenimine. LP = Lipofection. PS = Present study.

Despite attaining typical volumetric productivities, our specific plasmid and cell
productivities were lower than most previous studies. Indeed, because our volumetric
productivities were achieved at cell densities double to quadruple the density of all other
comparable studies, the ratio of virus particles produced per plasmid and per cell are in
most cases between 2 and 10-fold lower. This represents an area of substantial potential
for growth, with even marginal increases translating to significant gains in volumetric
productivity.
Process Scale
In the present work, transfection efficiency was estimated by the standard method
used in literature, where efficiency is represented by the percentage of GFP-expressing
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cells relative to the total cells present in the sample 48 hpt. We achieved transfection
efficiencies of almost 20% at cell densities higher than previously reported for
transfection of suspended cell cultures without complete medium replacement. This
represents a significant advancement towards improving volumetric productivity of
LVVs. Other studies have described transfection of HEK cells at high cell densities
(HCD) (≥3.0 up to 20.0 x 106 cells/mL), however these processes employ special means
of achieving elevated cell densities while maintaining cells in exponential growth, such
as by perfusion 19,39,49,50 or by centrifugal concentration of low density (~2 x 106
cells/mL), log-phase cells with medium replacement.51–55 While these methods increase
volumetric productivity, continuous biomanufacturing processes present unique
challenges in viral vector production (e.g., how to overcome packaging cell death from
extended virus production following transient transfection), and economic advantages at
manufacturing scale have yet to be demonstrated.56 Additionally, concentration of cells
by centrifugation and medium exchange become unrealistic at industrial scales. Batch
processes for biotherapeutic production are well defined, but are generally unable to
maintain high cell densities due to nutrient depletion and accumulation of toxic
metabolites.57 Further, a so-called “cell density effect” occurs in batch processes where
increases in cell concentration at transfection are connected to significant reductions in
transfection efficiency.58 Several attempts to characterize this effect in various
transfection/infection systems have been reported. Potential causes identified included
changes to intracellular pH, smaller cell size and decreased protrusion limiting DNA
uptake, and metabolic limitations at HCDs.59–62 Additionally, osmolality and
accumulation of lactate and ammonia were found to influence adenovirus titers at high
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cell densities.63 Interestingly, amino acid availability post-infection did not appear to
constrain adenovirus titers, though post-infection supplementation with other essential
nutrients (vitamins, sodium pyruvate and sodium acetate, lipids and precursors, and bases
and nucleosides) increased efficiency in one commercial medium, suggesting nutrient
limitations inhibit viral vector production in at least some formulations.
For production of HIV1 virus-like particles, Cervera et al. demonstrated that
limitations to transfection efficiency at HCD were not exclusively driven by nutrient
availability.28 Lavado-García et al. performed a metabolic analysis that showed
significant downregulation of nuclear transport machinery – importins and exportins that
transport DNA into and proteins out of the nucleus, respectively – as cell density at
transfection surpassed 3.0 x 106 cells/mL.29 This downregulation may have contributed to
the complete inhibition of transfection observed at 5.0 x 106 cells/mL. In contrast to
previous reports, we observed transfection efficiencies as high as 19.6% when
transfection was conducted at a density of 4.7 x 106 cells/mL. Further, a nearly 21-fold
increase in specific productivities was achieved by increasing pre-culture densities from
5.0 to 6.0 x 106 cells/mL. To our knowledge, this is the first demonstration that an
increase in transfection efficiency and cell specific viral productivity is associated with
increasing cell density at transfection cell densities above 4.0 x 106 cells/mL for batch
LVV production.
The actual cause of improved transfection efficiency at a density greater than 4.0
x 106 cells/mL is likely due to a combination of factors. Advances in chemically-defined
serum-free medium formulations allow for high density mammalian cultures without the
use of fed-batch or continuous feed supplementation.64 Our work presents preliminary
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evidence that a commercial medium can support increases in viral productivity at cell
densities greater than 2.0 x 106 cells/mL, which has not previously been reported for
batch processes.58 Uses of the LV-MAX lentiviral production system have been recently
published,65–68 however these were gene expression studies and did not focus on
optimizing LVV production for clinical applications.
The use of a commercial cationic-lipid transfection reagent may have also
contributed to higher transfection efficiency despite the cytotoxic effects in some cases
associated with lipofection.69 Additionally, a proprietary supplement and enhancer may
have worked in conjunction to overcome metabolic inhibitors to nuclear uptake of
transfected DNA. Finally, it has been previously demonstrated that the commercially
available LV-MAX cell line outperforms other HEK clones in LVV production, though
this was achieved at different conditions than those used in the present study; LV-MAX
cells were cultured in BalanCD with daily medium replacement.33
Regardless of cell density at the time of transfection, lot to lot variability is of
concern in transient LVV production systems, where successful co-transfection of 3 to 4
plasmids is necessary for generation of functional viral particles.70 Poor reproducibility in
vector titers can be partially mitigated by selection of an optimized gene carrier. For
example, transfection by cationic lipids tends to provide more reproducible efficiencies
compared to calcium phosphate precipitation.23 Among other potential factors, it is
understood that cell culture maintenance is a critical parameter in the production of
lentiviral vectors.71 However, the significance of this effect has not been adequately
investigated. In our experiments, lower vector titers were associated with cultures that
had sustained irregular passaging schedules several days prior to transfection. Even
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though the culture growth rates and viabilities had recovered and even surpassed those of
the highest LVV producing cultures by the day of transfection, it is possible that variation
in passage routine caused residual effects in metabolic processes important to high levels
of transgene expression. Carpentier et al. suggested that some cellular physiological state
exists that limits transport of pDNA to the nucleus and subsequent transcription.72
Follow-up research is necessary to assess which physiological characteristics or
metabolic pathways relevant to transfection efficiency might suffer from historical
inconsistencies in passaging.
Manufacturing Scale
Lentiviral vectors are desirable as clinical gene therapies due to their large
payloads, their ability to transduce non-dividing cells, and their integration of the
therapeutic transgene into target cell genomes. Suspended culture manufacturing
processes for production of lentiviral-based gene therapies could benefit from the
findings of this study. Specifically, culturing packaging cells to HCD prior to transfection
has practical advantages in addition to providing gains in volumetric titer. Traditional
scaleup of suspended culture requires the transfer of seed culture to several intermediate
vessels of increasing volumes. A final production-sized vessel is inoculated once enough
seed culture is available to provide an appropriate seeding density (Figure 10). Increasing
the maximum cell density a culture can support without losses to transfection efficiency
could enable seed trains to skip intermediate vessels, leading to faster scale-up.
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Figure 10. Example scaleup process for suspended culture. Created with
BioRender.com

For scalable technologies (fixed bed bioreactors, rockers with microcarriers, and
single-use stirred-tank bioreactors), pDNA production can account for as much as 28% of
the yearly cost per dose of a LVV gene therapy.73 This represents a basis for development
of stable producer cell lines which reduce or eliminate the use of plasmid. However,
advances in transient transfection processes to improve transfection efficiency would
yield similar plasmid-reduction benefits while maintaining flexible platforms for rapid
LVV design. In the present study, we demonstrated that for the same plasmid mass and
cell concentration at transfection, specific plasmid productivity could be increased by
culturing cells to higher densities pre-transfection. Implementation of this strategy –
culturing of packaging cells to high densities and subsequent dilution with fresh medium
immediately prior to transfection – could lead to higher specific plasmid productivities at
production-scale transfections (e.g., >500 L).
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New technologies for the large-scale production of DNA may further reduce the
economic challenges to transient transfection. Recent studies have demonstrated the
ability of DNA produced enzymatically by rolling circle amplification for use in LVV
production74 with infectious titers similar to those achieved by plasmid.75 When coupled
with production platforms optimized for transfection at HCD, the viability of transient
transfection for large-scale manufacture of lentiviral-based gene therapies becomes more
feasible.
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CHAPTER 5
CONCLUSIONS AND FUTURE WORK
In the present study, lentiviral vectors were produced by transient transfection in
suspended culture HEK293F cells in 125-mL shake flasks. Transfection was performed at
a high cell density of 4.7 x 106 cells/mL. The methods and reagents used to conduct
transfection followed a specific vendor protocol. Volumetric productivity, viral gene
copies per milliliter of culture, was 7.3 x 108, which is approximately equivalent to 7.3 x
106 transducing units per milliliter. This was within a range reported by three
comparable studies, which ranged from 0.23 to 1.7 x 107 TU/mL. Specific plasmid
productivity, 1.5 x 106 TU/ug plasmid, was lower than all three comparable reports which
ranged from 0.23 to 1.7 x 107 TU/ug plasmid, suggesting that increases in plasmid
productivity are possible, which would provide further increases to the volumetric and
specific biomass productivities. Cells in which velocity and viability were maintained
consistently prior to transfection without significant decreases due to exhaustion of
growth medium provided continuous increases in vector titer with cell density pretransfection up to 6.0 x 106 cells/mL, after which a decline in viral gene copies per
culture volume was observed. This decline was observed up to pre-transfection cell
densities of 6.8 x 106 cells/mL, which was the highest density tested in this study. To our
knowledge, the LV-MAX lentiviral production system is the first commercial platform
discussed in peer-reviewed literature to demonstrate volumetric titers of lentivirus
produced by transient transfection of high density (>3.0 x 106 cells/mL) suspended
cultures in batch mode comparable to titers from cells transfected at low density (<3.0 x
106 cells/mL).
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Given the results of the present work, the following areas of investigation are
warranted as the focus of future studies:
1. Determining transfection efficiencies of cells cultured to densities greater than 6.8
x 106 cells/mL prior to being diluted to 4.7 x 106 cells/mL for transfection, and
efficiencies when transfecting at cell densities above 4.7 x 106 cells/mL. Are the
declines in LVV titers we observed at higher densities due to nutrient exhaustion,
build-up of toxic metabolites, cell death post-transfection, or some combination of
these factors?
2. Examining the effect of dilution on transfection efficiency. Additionally, how
does the nutrient requirement of the cells change following successful transfection
versus non-transfected cells at high cell density? How does the level of dilution
influence the viability and density of cells following transfection?
3. Elucidating the effect of passage routine on LVV titer. If a cell culture falls out of
exponential growth several days prior to transfection but recovers by the day of
transfection, are there metabolic pathways or physiological characteristics
important to transfection and gene expression that might still be in an altered state
independent of the cell growth rate or viability?
4. What other changes to the transfection process (adjuvants, nutrients in growth
medium, etc.) can improve the specific plasmid productivity at high cell
densities?
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Appendix A: Supplementary Information
Supplemental Figures

Figure 11. Plasmid map of pLJM1-EGFP lentiviral backbone plasmid. Retrieved
from https://www.addgene.org/19319/#19319-DNA.cg.
Equation 1
Plasmid copy number was approximated from plasmid mass using the following
equation:
𝑛𝑛𝑛𝑛.
(𝑚𝑚 ∗
)
𝑚𝑚𝑚𝑚𝑚𝑚
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑁𝑁𝑁𝑁. =
𝑏𝑏𝑏𝑏 ∗ 𝑀𝑀𝑀𝑀
Where
m = mass of plasmid
no./mol = 6.022 x 1023 molecules per mole (Avogadro’s number)
bp = the length of the plasmid in base pairs
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MW = 650 g/mol, or the average molecular weight of a base pair.
As an example, for 10 nanograms of the pLJM1-EGFP plasmid, which has a length of
8,083 bp, Equation 1 becomes:
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑁𝑁𝑁𝑁. =

(10 𝑛𝑛𝑛𝑛 ∗ 6.022 ∗ 1023 )
= 1.12 ∗ 109 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
8,083 ∗ 650

Equation 2
Plasmid copy number was approximated from plasmid mass using the following
equation:
−1

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 (%) = �10𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 1� 𝑥𝑥 100
Equation 3
Specific volumetric productivity in transducing units per milliliter was calculated as
follows:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
=

102 𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢
𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑜𝑜𝑜𝑜 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∗

Equation 4
Specific plasmid productivity in transducing units per microgram of plasmid used for
transfection was calculated as follows:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
=
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∗ 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑎𝑎𝑎𝑎 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
=
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 ∗
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
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Equation 5
Specific biomass productivity in transducing units per viable cell used for transfection
was calculated as follows:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 =

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑎𝑎𝑎𝑎 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
=
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
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Appendix B: Figure Publication Licenses
Publication license for Figure 2.

58
Publication license for Figure 3.

59
Publication license for Figure 10.

